The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma
Open accessAbstract
Chondrosarcoma is a heterogeneous collection of malignant bone tumors and is the second most common primary malignancy of bone after osteosarcoma. Recent work has identified frequent, recurrent mutations in IDH1 or IDH2 in nearly half of central chondrosarcomas. However, there has been little systematic genomic analysis of this tumor type, and, thus, the contribution of other genes is unclear. Here we report comprehensive genomic analyses of 49 individuals with chondrosarcoma (cases). We identified hypermutability of the major cartilage collagen gene COL2A1, with insertions, deletions and rearrangements identified in 37% of cases. The patterns of mutation were consistent with selection for variants likely to impair normal collagen biosynthesis. In addition, we identified mutations in IDH1 or IDH2 (59%), TP53 (20%), the RB1 pathway (33%) and Hedgehog signaling (18%).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Self-citationAmary, M. F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., Pollock, R., O'Donnell, P., Grigoriadis, A., Diss, T., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2913 · Cited by 1,023
Self-citation
Cited by
Lost in translation: animal models and clinical trials in cancer treatment.
(2014) · Europe PMC (PubMed Central) · Cited by 1,033
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Bolli, N., Avet-Loiseau, H., Wedge, D. C., Van Loo, P., Alexandrov, L. B., Martincorena, I., Dawson, K. J., Iorio, F., Nik-Zainal, S., Bignell, G. R., et al. (2014) · Nature Communications · doi:10.1038/ncomms3997 · Cited by 875
Self-citationDistinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone
Behjati, S., Tarpey, P. S., Presneau, N., Scheipl, S., Pillay, N., Van Loo, P., Wedge, D. C., Cooke, S. L., Gundem, G., Davies, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2814 · Cited by 854
Self-citationThe role of collagen in cancer: from bench to bedside
Xu, S., Xu, H., Wang, W., Li, S., Li, H., Li, T., Zhang, W., Yu, X., & Liu, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2058-1 · Cited by 735
Crystal Structure of TET2-DNA Complex: Insight into TET-Mediated 5mC Oxidation
Hu, L., Li, Z., Cheng, J., Rao, Q., Gong, W., Liu, M., Shi, Y. G., Zhu, J., Wang, P., & Xu, Y. (2013) · Cell · doi:10.1016/j.cell.2013.11.020 · Cited by 450
The 2020 WHO Classification of Tumors of Bone: An Updated Review
Choi, J. H., & Ro, J. Y. (2021) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000293 · Cited by 395
Recurrent PTPRB and PLCG1 mutations in angiosarcoma
Behjati, S., Tarpey, P. S., Sheldon, H., Martincorena, I., Van Loo, P., Gundem, G., Wedge, D. C., Ramakrishna, M., Cooke, S. L., Pillay, N., et al. (2014) · Nature Genetics · doi:10.1038/ng.2921 · Cited by 308
Self-citationBehjati, S., Tarpey, P. S., Haase, K., Ye, H., Young, M. D., Alexandrov, L. B., Farndon, S. J., Collord, G., Wedge, D. C., Martincorena, I., et al. (2017) · Nature Communications · doi:10.1038/ncomms15936 · Cited by 261
Self-citationCells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?
Mutsaers, A. J., & Walkley, C. R. (2014) · Bone · doi:10.1016/j.bone.2014.02.003 · Cited by 233
Biology of Bone Sarcomas and New Therapeutic Developments
Brown, H. K., Schiavone, K., Gouin, F., Heymann, M.-F., & Heymann, D. (2018) · Calcified Tissue International · doi:10.1007/s00223-017-0372-2 · Cited by 163
Mutant IDH is sufficient to initiate enchondromatosis in mice
Hirata, M., Sasaki, M., Cairns, R. A., Inoue, S., Puviindran, V., Li, W. Y., Snow, B. E., Jones, L. D., Wei, Q., Sato, S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424400112 · Cited by 115
Aran, V., Devalle, S., Meohas, W., Heringer, M., Cunha Caruso, A., Pinheiro Aguiar, D., Leite Duarte, M. E., & Moura Neto, V. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103340 · Cited by 87
Interpretation of cancer mutations using a multiscale map of protein systems
Zheng, F., Kelly, M. R., Ramms, D. J., Heintschel, M. L., Tao, K., Tutuncuoglu, B., Lee, J. J., Ono, K., Foussard, H., Chen, M., et al. (2021) · Science · doi:10.1126/science.abf3067 · Cited by 81
Gutteridge, A., Rathbone, V. M., Gibbons, R., Bi, M., Archard, N., Davies, K. E. J., Brown, J., Plagnol, V., Pillay, N., Amary, F., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1146 · Cited by 38
Self-citationPalmerini, E., Lopez Pousa, A., Grignani, G., Redondo, A., Hindi, N., Provenzano, S., Sebio, A., Lopez Martin, J. A., Valverde, C., Martinez Trufero, J., et al. (2025) · Cancer · doi:10.1002/cncr.35628 · Cited by 29
“21 Recently, an article assessing targeted DNA sequencing, showed that DDCS, as compared with conventional chondrosarcoma, had a higher TMB. 22 28–31 Furthermore, osteosarcoma lacks programmed death ‐ ligand 1 (PD ‐ L1) expression on tumor cells, 23,24 with a small proportion of cases immune ‐ hot…”
Lyskjær, I., Davies, C., Strobl, A., Hindley, J., James, S., Lalam, R. K., Cross, W., Hide, G., Rankin, K. S., Jeys, L., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13102 · Cited by 16
Metadata
- Authors
- Tarpey, P. S., Behjati, S., Cooke, S. L., Van Loo, P., Wedge, D. C., Pillay, N., Marshall, J., O'Meara, S., Davies, H., Nik-Zainal, S., Beare, D., Butler, A., Gamble, J., Hardy, C., Hinton, J., Jia, M. M., Jayakumar, A., Jones, D., Latimer, C., Maddison, M., Martin, S., McLaren, S., Menzies, A., Mudie, L., Raine, K., Teague, J. W., Tubio, J. M. C., Halai, D., Tirabosco, R., Amary, F., Campbell, P. J., Stratton, M. R., Flanagan, A. M., & Futreal, P. A.
- Venue
- Nature Genetics
- Published
- 2013-06-16
- Volume
- 45
- Issue
- 8
- Pages
- 923-926
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2069329627
- Cited by
- 221
- References
- 2
- FWCI
- 13.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.